Introduction
Methods
Results
The current ethical provisions applicable in Europe to inherited neurometabolic diseases
Document | Relevant topics | Specific provisions | |||
---|---|---|---|---|---|
Paediatric issues | Rare diseases | Inherited/genetic issues | Mental disability/vulnerability | ||
Regulation (EU) 536/2014 | Authorisation and conduct of trials, ethics committees, informed consent and assent process, vulnerability, minors, data protection and confidentiality, protocol | Art. 10, 32, 35 Recitals 19, 27 | Recitals 9, 10 | Art. 10, 28, 29, 31, 35 Recitals 15, 19, 27 | |
Directive 2005/28/EC | Conduct of the trial, ethics committee | n.s. | n.s. | n.s. | n.s. |
ICH Topic E 6 (R1) Guideline | Conduct of trials, informed consent, clinical trial protocol, ethics committee, vulnerability | Par. 4.8.12 | n.s. | n.s. | Par. 1.61, 3.1.1, 4.8.12 |
EMA Reflection paper on clinical trials conducted outside EU/EEA | Conduct of multi-national trials, informed consent and assent process, ethics committee, confidentiality vulnerability, design of clinical trials | 4.2, 4.3, 4.5, 5 | 5.1, 5.2 | 4.2, 4.5 | |
EC guidelines on advanced therapy medicinal products | Conduct of trials with advanced therapies, clinical trial protocol | n.s. | n.s. | n.s. | n.s. |
EU Charter of Fundamental rights | Children’s rights | Art. 24 | n.s. | n.s. | n.s. |
Declaration of Helsinki | Conduct of human research, vulnerability, risk/benefit, ethics committee, informed consent, privacy and confidentiality | 19, 20, 28, 29 | n.s. | n.s. | 19, 20, 28, 29, 30 |
Oviedo Convention | Informed consent, subjects unable to give the consent, persons who have a mental disorder, subject’s rights | Art. 12 | Art. 6, 7, 17 | ||
Additional Protocol to the Oviedo Convention | Risk/benefit, ethics committee, information and consent, privacy and confidentiality, vulnerability | Art. 15 | n.s. | n.s. | Art. 15 |
Recommendation Rec(2006)4 | Biological samples handling, information and consent, privacy and confidentiality | n.s. | n.s. | n.s. | n.s. |
CIOMS-WHO guidelines 2002 | Informed consent, clinical trial protocol, ethics committee, benefit/risk, vulnerability, privacy and confidentiality, secondary use of data | Guideline 14 | n.s. | Guidelines 4, 5, 8, 18 | Guidelines 4, 9, 13, 15 |
Directive 95/46/EC | Data protection and confidentiality, informed consent, subjects unable to give the consent, subject’s rights (art. 1-8; 10-34) | n.s. | n.s. | n.s. | n.s. |
Directive 2001/83/EC | Data protection and retention, confidentiality (art. 21, 5.2.c) | n.s. | n.s. | n.s. | n.s. |
Recommendation No. R (97) 5 | Data protection and confidentiality, informed consent, subjects unable to give the consent, subject’s rights | n.s. | n.s. | 4.7 | 12.2 |
Convention of 28 January 1981 | Data protection and retention | n.s. | n.s. | n.s. | n.s. |
UNESCO Declaration on Human Genetic Data, 2003 | Informed consent, subjects unable to give the consent, biological samples, ethics committee, data protection and confidentiality | n.s. | n.s. | Whole document focused on genetic issues | n.s. |
Recommendation No. R (92) 3 | Informed consent, minors, persons suffering from mental disorders, data protection and handling, confidentiality | Principle 5 | n.s. | Principle 5 | |
ICH Topic E 11 | Design and conduct of paediatric trials, assent, information, ethics committee | Whole document focused on paediatric issues | n.s. | n.s. | 2.6.3 |
Ethical Recommendations, 2008 | Design and conduct of paediatric trials, assent, information, ethics committee, risk/benefit, data protection, disclosure of genetic findings | 6.1, 9.1 | 9.1, 18 | ||
Paediatric Regulation (EC) 1901-1902/2006 | Balance between the development of well-studied medicines and ethical concerns for enrolling young patients (Recital 7) | n.s. | n.s. | n.s. |
The application of ethical provisions retrieved in the literature
Source | Fields | Relevant topics | Recommendations/suggestions |
---|---|---|---|
Ross, 2010 [47] | Newborn genetic screening | - Use of stored samples for research - Parents’ informed consent | - To seek for the consent from parents for research on stored sample storage and research |
Simopoulos, 2009 [50] | Newborn genetic screening | - Appropriateness of the investigation | - To protect individuals identified by genetic screening against the psychological and social hazards |
Glantz et al., 2008 [38] | Biobanks | - Use of stored samples for research - Informed consent for secondary use - Owner of stored samples | - To establish clear rules on the use of samples in medical research and genetic privacy when information is used by companies - To provide participants the right to withdraw the consent |
Botkin, 2005 [3] | Newborn genetic screening | - Use of stored samples for research - Appropriateness of the investigation | - To apply an approach to evaluate screening tests as rigorous as the approach for drugs (phases I to IV) |
Sheela et al., 2005 [49] | Trials/experimental uses | - Parents’ informed consent - Vulnerable status - Approval from the ethics committee | - To provide full and appropriate information to parents - To offer adequate time for the parents to absorb information |
Gelsinger, 2002 [35] | Trials/experimental uses | - Informed consent - Potential benefits, risks and discomforts | - To provide full and appropriate information - To carefully review paediatric protocols |
Merz et al., 2002 [43] | Genetic research | - Use of stored samples for research - Parents’ informed consent - Rights of research participants and children | - To address issues on the control of research results and the sharing of benefits before the research is performed - To involve research participants in decision-making - To develop policies for protecting the interests of subjects |
Clague, Thomas, 2002 [7] | Newborn genetic screening | - Secondary use of samples for research - Parents’ informed consent for secondary use - Right to privacy and anonymised data - Appropriateness of the investigation | - To undertake long-term storage, to allow re-evaluation of apparently erroneous results - To perform anonymously research |
Pschera, 2000 [44] | Trials/experimental uses | - Appropriateness of the investigation | - To enhance the methodology for a safe and broad application of experimental approaches |
Fox,. 2000 [34] | Trials/experimental uses | - Informed consent for gene therapy trials - Disclosure of conflicts of interest | - To provide full and appropriate information - To disclosure conflicts of interest |
During, 1996 [18] | Trials/experimental uses | - Informed consent - Expertise in ethics committees | - To provide full and appropriate information - To foresee specific expertise in ethics committee on gene therapy |
Project | Fields | Relevant topics | Outcomes |
---|---|---|---|
BIONET [1] | Genetic research | - Ethical governance and regulation of research in China and EU | No relevant public information |
COB [8] | Genetic research | - Cultural diversity and harmonisation of governance in Europe | No relevant public information—recommendations for policy makers not publicly available |
Ethical, Legal and Social aspects of Brain Research [19] | Neurological disorders | - Ethical, legal and social aspects of brain research | - Need to define ethical and legal standards specifically applicable to brain research |
InNerMeD-I-Network [40] | Rare inherited, paediatric, neurological diseases | - Ethical issues on clinical research, informed consent, vulnerable patients, regulatory, ethics committees | - Recommendations for researchers, ethics committees and patients to conduct studies involving iNMD patients with the highest ethical standards |
LEUKOTREAT [41] | Rare inherited, paediatric, neurological diseases | - Informed consent - Ethical impacts of the proposed therapeutic challenges - Data sharing | - Identification of patient’ expectations towards research - A charter on data sharing within the project database - Recommendations on data processing, participant information - Template of information sheet for patients and families |
RD-CONNECT [45] | Rare diseases | - Informed consent - Data protection - Data sharing - Registries - Biobanks | - Guidelines and standards for informed consent procedures, including essential elements to be dealt with and templates of prospective, retrospective and broad consent - Recommendations for researchers on the informed consent with specific information on data sharing - Appropriate time to think and ask questions for participants - To consult patients/participant representatives on the quality of information - Guidelines for effective and ethical data and sample sharing [42] |
RESPECT [46] | Paediatrics | - Participation and empowerment of children in clinical trials, expectations and needs - Informed consent/assent | - Main barriers to participation of children in clinical trials identified - Recommendations for investigators, sponsors, patient organisations and policy makers |
SCPE network [48] | Neurological paediatric diseases | - Informed consent | No relevant public information |
TEDDY [51] | Paediatrics | - Informed consent/assent process - Minimal risks/burden - Emergency situations - Placebo use - Confidentiality and privacy, right to information - Contents of documents to be submitted to ethics committee - Compensation for damage | - To achieve agreed common definitions and procedures in the European Union with reference to genetic tests and studies - To adopt special measures, taking into account developmental needs of children at different ages and individual variations between children of the same age |